Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

by Zacks Equity Research Published on April 17,2019

Key highlights of the past week are collaborations and pipeline updates.

• NVO Quick QuoteNVONegative Net Change
• BMY Quick QuoteBMYPositive Net Change
• GILD Quick QuoteGILDPositive Net Change
• CELG Quick QuoteCELGPositive Net Change
• AXSM Quick QuoteAXSMNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• VRTX Quick QuoteVRTXNegative Net Change

• biotechs

ProQR Initiates Dosing in Phase II/III Eye Disorder Study

by Zacks Equity Research Published on April 16,2019

ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

• EXEL Quick QuoteEXELNegative Net Change
• PRQR Quick QuotePRQRNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• CLSN Quick QuoteCLSNNegative Net Change

• biotechs

Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

by Zacks Equity Research Published on April 16,2019

Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.

• MRUS Quick QuoteMRUSNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• PDLI Quick QuotePDLINo Net Change
• XON Quick QuoteXONPositive Net Change

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

by Zacks Equity Research Published on November 09,2018

Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.

• OGEN Quick QuoteOGENNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• ZIOP Quick QuoteZIOPPositive Net Change
• XON Quick QuoteXONPositive Net Change

• pharmaceuticals

Intrexon Reports Preliminary Earnings and Revenues for Q2

by Zacks Equity Research Published on August 10,2018

Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.

• BMY Quick QuoteBMYPositive Net Change
• ZIOP Quick QuoteZIOPPositive Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• XON Quick QuoteXONPositive Net Change

What's in Store for Intrexon (XON) This Earnings Season?

by Zacks Equity Research Published on July 31,2018

Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.

• FCSC Quick QuoteFCSCPositive Net Change
• ENDP Quick QuoteENDPPositive Net Change
• PCRX Quick QuotePCRXPositive Net Change
• XON Quick QuoteXONPositive Net Change

4 Best Performing Biotech Stocks of June: More Room to Run?

by Indrajit Bandyopadhyay Published on July 05,2018

Biotech industry experiences a turnaround in June. Here are four stocks riding the rally.

• FCSC Quick QuoteFCSCPositive Net Change
• QURE Quick QuoteQURENegative Net Change
• ATNX Quick QuoteATNXPositive Net Change
• RYTM Quick QuoteRYTMNegative Net Change

Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on June 01,2018

Fibrocell Science, Inc. (FCSC) has been struggling lately, but the selling pressure may be coming to an end soon

• FCSC Quick QuoteFCSCPositive Net Change

What's in Store for Intrexon (XON) This Earnings Season?

by Zacks Equity Research Published on May 02,2018

Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.

• CELG Quick QuoteCELGPositive Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• ADVM Quick QuoteADVMNegative Net Change

Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research Published on March 02,2018

Intrexon's (XON) loss in the fourth quarter of 2017 was narrower than expected.

• ZIOP Quick QuoteZIOPPositive Net Change
• LGND Quick QuoteLGNDNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change

What's in Store for Intrexon (XON) This Earnings Season?

by Zacks Equity Research Published on February 26,2018

Investor focus are likely to remain on Intrexon's (XON) performance along with other developmental updates during the quarterly call.

• FCSC Quick QuoteFCSCPositive Net Change
• ATRA Quick QuoteATRANegative Net Change
• GEMP Quick QuoteGEMPPositive Net Change

What's in Store for Cardinal Health (CAH) in Q2 Earnings?

by Zacks Equity Research Published on January 30,2018

Pricing pressure in generics portfolio is likely to mar Cardinal Health's (CAH) top line in Q2.

• AMPH Quick QuoteAMPHNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• ANTH Quick QuoteANTHNo Net Change

Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?

by Zacks Equity Research Published on January 29,2018

Molecular Diagnostics unit's stellar performance in the first quarter of 2018 is likely to drive Hologic (HOLX) in Q1.

• AMPH Quick QuoteAMPHNegative Net Change
• HOLX Quick QuoteHOLXPositive Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• ANTH Quick QuoteANTHNo Net Change

Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?

by Zacks Equity Research Published on January 29,2018

Cerner (CERN) expects solid Q4 revenues on a surge in bookings. Stiff competition remains a concern.

• CERN Quick QuoteCERNPositive Net Change
• AMPH Quick QuoteAMPHNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• ANTH Quick QuoteANTHNo Net Change

Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

by Zacks Equity Research Published on January 23,2018

Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.

• ABBV Quick QuoteABBVNegative Net Change
• TECH Quick QuoteTECHNegative Net Change
• SYK Quick QuoteSYKNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change

Top Ranked Momentum Stocks to Buy for January 23rd

by Zacks Equity Research Published on January 23,2018

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:

• UNH Quick QuoteUNHPositive Net Change
• TECH Quick QuoteTECHNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• BOOT Quick QuoteBOOTNegative Net Change

Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research Published on November 10,2017

Intrexon (XON) reported narrower-than-expected loss but revenues missed estimates in the third quarter of 2017. The company remains focused on the development of its pipeline candidates.

• ZIOP Quick QuoteZIOPPositive Net Change
• LGND Quick QuoteLGNDNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change

What's in Store for Intrexon (XON) This Earnings Season?

by Zacks Equity Research Published on October 31,2017

Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.

• FCSC Quick QuoteFCSCPositive Net Change
• AGEN Quick QuoteAGENNegative Net Change
• CLVS Quick QuoteCLVSPositive Net Change

Implied Volatility Surging for Fibrocell Science (FCSC) Stock Options

by Zacks Equity Research Published on September 22,2017

Investors need to pay close attention to Fibrocell Science (FCSC) stock based on the movements in the options market lately.

• FCSC Quick QuoteFCSCPositive Net Change

What's in Store for Intrexon (XON) in this Earnings Season?

by Zacks Equity Research Published on August 02,2017

Intrexon Corporation (XON) will focus on the development of its pipeline candidates- FCX-013, FCX-007 in Q2.

• FCSC Quick QuoteFCSCPositive Net Change
• TSRO Quick QuoteTSRONo Net Change
• ESPR Quick QuoteESPRNegative Net Change

Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9%

by Zacks Equity Research Published on June 20,2017

Fibrocell Science, Inc. (FCSC) moved big last session, as its shares rose almost 14% on the day.

• VVUS Quick QuoteVVUSPositive Net Change
• FCSC Quick QuoteFCSCPositive Net Change

Intrexon (XON) Q1 Loss Wider than Expected, Revenues Beat

by Zacks Equity Research Published on May 11,2017

Intrexon Corporation (XON) reported loss per share of 26 cents in the first quarter of 2017, which was wider than the Zacks Consensus Estimate loss of 23 cents.

• ZIOP Quick QuoteZIOPPositive Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• GNVC Quick QuoteGNVCNegative Net Change

Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?

by Zacks Equity Research Published on May 02,2017

Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.

• FCSC Quick QuoteFCSCPositive Net Change
• AUPH Quick QuoteAUPHNegative Net Change
• FGEN Quick QuoteFGENNegative Net Change

Intrexon (XON) Q4 Loss Wider than Expected, Revenues Lag

by Zacks Equity Research Published on March 03,2017

Intrexon reported adjusted loss per share of 26 cents in the fourth quarter of 2016 wider than the Zacks Consensus Estimate loss of 23 cents.

• FCSC Quick QuoteFCSCPositive Net Change
• XON Quick QuoteXONPositive Net Change
• SNSS Quick QuoteSNSSPositive Net Change
• OGEN Quick QuoteOGENNegative Net Change

New Strong Buy Stocks for June 30th

by Swarup Gupta Published on June 30,2016

Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

• CGNX Quick QuoteCGNXNegative Net Change
• ENS Quick QuoteENSNegative Net Change
• FCSC Quick QuoteFCSCPositive Net Change
• TRMK Quick QuoteTRMKNegative Net Change